JP2016507502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507502A5 JP2016507502A5 JP2015549756A JP2015549756A JP2016507502A5 JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5 JP 2015549756 A JP2015549756 A JP 2015549756A JP 2015549756 A JP2015549756 A JP 2015549756A JP 2016507502 A5 JP2016507502 A5 JP 2016507502A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heterocyclyl
- carbocyclyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 121
- 125000000623 heterocyclic group Chemical group 0.000 claims 59
- 229910052799 carbon Inorganic materials 0.000 claims 43
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 125000004452 carbocyclyl group Chemical group 0.000 claims 37
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 3
- -1 CN Inorganic materials 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 102000008122 Casein Kinase I Human genes 0.000 claims 1
- 108010049812 Casein Kinase I Proteins 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740564P | 2012-12-21 | 2012-12-21 | |
| US61/740,564 | 2012-12-21 | ||
| PCT/US2013/076795 WO2014100533A1 (en) | 2012-12-21 | 2013-12-20 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507502A JP2016507502A (ja) | 2016-03-10 |
| JP2016507502A5 true JP2016507502A5 (enExample) | 2017-01-12 |
| JP6267231B2 JP6267231B2 (ja) | 2018-01-24 |
Family
ID=49943572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549756A Expired - Fee Related JP6267231B2 (ja) | 2012-12-21 | 2013-12-20 | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9556179B2 (enExample) |
| EP (1) | EP2935271B1 (enExample) |
| JP (1) | JP6267231B2 (enExample) |
| CN (1) | CN105073751B (enExample) |
| WO (1) | WO2014100533A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6283688B2 (ja) | 2012-12-21 | 2018-02-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン |
| EP3157925B1 (en) * | 2014-06-19 | 2019-12-18 | Bristol-Myers Squibb Company | Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors |
| CN107207531B (zh) * | 2014-11-21 | 2021-05-25 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的稠合的咪唑衍生物 |
| US9884868B2 (en) * | 2015-03-02 | 2018-02-06 | Rigel Pharmaceuticals, Inc. | TGF-beta inhibitors |
| CN107847480B (zh) | 2015-03-23 | 2021-06-25 | 墨尔本大学 | 呼吸性疾病的治疗 |
| WO2017020981A1 (en) | 2015-07-31 | 2017-02-09 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| KR102640385B1 (ko) * | 2016-09-21 | 2024-02-23 | 벡투스 바이오시스템즈 리미티드 | 고혈압 및/또는 폐 섬유증 치료용 조성물 |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| DK3774795T3 (da) * | 2018-03-29 | 2022-06-27 | Univ Masarykova | 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer |
| JP7646132B2 (ja) * | 2018-09-09 | 2025-03-17 | カナートファーマ アーゲー | 血管疾患の治療におけるカゼインキナーゼ１阻害剤の使用 |
| WO2020093098A1 (en) | 2018-11-07 | 2020-05-14 | The University Of Melbourne | Novel compounds for the treatment of respiratory diseases |
| US11739078B2 (en) * | 2019-02-22 | 2023-08-29 | Insilico Medicine Ip Limited | Methods of inhibiting kinases |
| US11530197B2 (en) | 2021-02-24 | 2022-12-20 | Insilico Medicine Ip Limited | Analogs for the treatment of disease |
| WO2025231112A1 (en) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Sik2 modulators and uses thereof |
| WO2025231117A1 (en) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Sik2 modulators and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1532118A2 (en) * | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JPWO2008016131A1 (ja) * | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US8188083B2 (en) * | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
| US8703811B2 (en) | 2008-05-07 | 2014-04-22 | Genzyme Corporation | Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| FR2940285A1 (fr) | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| RS53246B (sr) | 2009-10-28 | 2014-08-29 | Pfizer Inc. | Derivati imidazola kao inhibitori kazein kinaze |
| JP6283688B2 (ja) | 2012-12-21 | 2018-02-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン |
-
2013
- 2013-12-20 JP JP2015549756A patent/JP6267231B2/ja not_active Expired - Fee Related
- 2013-12-20 US US14/653,895 patent/US9556179B2/en active Active
- 2013-12-20 WO PCT/US2013/076795 patent/WO2014100533A1/en not_active Ceased
- 2013-12-20 CN CN201380073382.4A patent/CN105073751B/zh not_active Expired - Fee Related
- 2013-12-20 EP EP13818937.8A patent/EP2935271B1/en not_active Not-in-force